adalimumab + methotrexate
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Early Rheumatoid Arthritis
Conditions
Early Rheumatoid Arthritis
Trial Timeline
Oct 1, 2010 → Sep 1, 2012
NCT ID
NCT01185301About adalimumab + methotrexate
adalimumab + methotrexate is a phase 3 stage product being developed by AbbVie for Early Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01185301. Target conditions include Early Rheumatoid Arthritis.
What happened to similar drugs?
1 of 20 similar drugs in Early Rheumatoid Arthritis were approved
Approved (1) Terminated (1) Active (18)
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02196701 | Phase 3 | Completed |
| NCT01185301 | Phase 3 | Completed |
| NCT01185288 | Approved | Completed |
| NCT01162421 | Approved | Completed |
| NCT00808509 | Approved | Completed |
| NCT00783510 | Pre-clinical | Completed |
Competing Products
20 competing products in Early Rheumatoid Arthritis